Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the role of physical exercise after surgery for gastric cancer? A scoping review.

ESMO gastrointestinal oncology·2026
Same author

RENEB Inter-Laboratory Comparison 2021: Inter-Assay Comparison of Eight Dosimetry Assays.

Radiation research·2023
Same author

RENEB Inter-Laboratory Comparison 2021: The Cytokinesis-Block Micronucleus Assay.

Radiation research·2023
Same author

RENEB Inter-Laboratory Comparison 2021: The Dicentric Chromosome Assay.

Radiation research·2023
Same author

A NOVEL BIOLOGICAL DOSIMETRY ASSAY AS A POTENTIAL TOOL FOR TRIAGE DOSE ASSESSMENT IN CASE OF LARGE-SCALE RADIOLOGICAL EMERGENCY.

Radiation protection dosimetry·2019
Same author

Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: A case-control study.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2017
Same journal

RNA Sequencing Indicates Distinct Platelet Transcriptomic Changes in Immune Thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Joint effect of muscle strength and physical inactivity on risk of incident venous thromboembolism: The Tromsø Study.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na<sup>+</sup> Binding and Preferentially Hinders the Protease Anticoagulant Functions.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

A historical review of the biological, semantic and clinical aspects of aspirin resistance.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Association between Thrombus Neutrophil Extracellular Traps Content and Ischemic Stroke Recurrence.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis.

Journal of thrombosis and haemostasis : JTH·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Aspirin, 110 years later.

C Patrono1, B Rocca

  • 1Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. carlo.patrono@rm.unicatt.it

Journal of Thrombosis and Haemostasis : JTH
|July 28, 2009
PubMed
Summary
This summary is machine-generated.

Aspirin, initially an analgesic, is now a key antiplatelet drug. Ongoing research debates optimal dosing, patient resistance, and its use in preventing cardiovascular events.

More Related Videos

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Related Experiment Videos

Last Updated: Jun 21, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Acetylsalicylic acid (aspirin) was developed as a pain reliever with better gastric tolerance than salicylates.
  • Its antiplatelet properties were recognized decades later, revolutionizing cardiovascular prevention strategies.

Observation:

  • Aspirin's antiplatelet mechanism of action was elucidated approximately 90 years after its introduction.
  • Development of biomarkers and randomized trials confirmed low-dose aspirin's efficacy and safety.

Findings:

  • Despite its long history, optimal aspirin dosage for maximizing efficacy and minimizing toxicity remains debated.
  • The phenomenon of patient 'resistance' to aspirin's antiplatelet effects is an active area of research.
  • Balancing the benefits and risks of aspirin for primary versus secondary prevention is a critical clinical consideration.

Implications:

  • Further research is needed to personalize aspirin therapy based on individual patient responses and risk factors.
  • Understanding aspirin resistance could lead to alternative antiplatelet strategies for non-responders.
  • Clarifying the benefit-risk profile will refine guidelines for aspirin use in diverse patient populations.